Cytarabine in Treating Young Patients With Recurrent or Refractory Ewing's Sarcoma
Trial ID or NCT#
NCT00470275
Status
NOT RECRUITING
Purpose
RATIONALE: Drugs used in chemotherapy, such as cytarabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well cytarabine works in treating young patients with recurrent or refractory Ewing's sarcoma.
Official Title
Phase II Trial of Intermediate-Dose Cytarabine to Modulate EWS/FLI for Children and Young Adults With Recurrent or Refractory Ewing Sarcoma
Eligibility Criteria
Ages Eligible for Study: Younger than 30 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: No
Investigator(s)
Neyssa Marina
Contact us to find out if this trial is right for you.
Contact
Min Wang
6507364281
View on ClinicalTrials.gov
